Overall survival after transarterial lipiodol infusion chemotherapy with or without embolization for unresectable hepatocellular carcinoma: Propensity score analysis

American Journal of Roentgenology

Volumn 194, Issue 3, 2010, Pages 830-837

  Takayasu, Kenichi ^a   Arii, Shigeki ^b   Ikai, Iwao ^c   Kudo, Masatoshi ^d   Matsuyama, Yutaka ^e   Kojiro, Masamichi ^f   Makuuchi, Masatoshi ^g  

^a NATIONAL CANCER CENTER HOSPITAL   (Japan)

^b TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^c KYOTO UNIVERSITY   (Japan)

^d KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^e UNIVERSITY OF TOKYO   (Japan)

^f KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^g JAPANESE RED CROSS MEDICAL CENTER   (Japan)

Author keywords

Chemotherapy; Hepatocellular carcinoma; Iodized oil infusion; Propensity analysis; Transarterial chemoembolization

Indexed keywords

ANTINEOPLASTIC AGENT; GELATIN SPONGE; IODINATED POPPYSEED OIL;

ADULT; AGED; ARTICLE; ARTIFICIAL EMBOLISM; CANCER MORTALITY; CANCER STAGING; CANCER SURVIVAL; CHEMOEMBOLIZATION; CONTROLLED STUDY; EMULSION; FEMALE; FOLLOW UP; HAZARD RATIO; HUMAN; LIVER CELL CARCINOMA; LIVER INJURY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; TUMOR VOLUME;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, HEPATOCELLULAR; CHEMOEMBOLIZATION, THERAPEUTIC; CHI-SQUARE DISTRIBUTION; CISPLATIN; COMBINED MODALITY THERAPY; DIAGNOSTIC IMAGING; DOXORUBICIN; EPIRUBICIN; FEMALE; HUMANS; IODIZED OIL; LIVER NEOPLASMS; LOGISTIC MODELS; MALE; MIDDLE AGED; MITOMYCIN; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; QUESTIONNAIRES; SURVIVAL RATE; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; ZINOSTATIN;

EID: 77749298647     PISSN: 0361803X     EISSN: None     Source Type: Journal    
DOI: 10.2214/AJR.09.3308     Document Type: Article

References (39)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Estimating the world cancer burden: Globocan 2000. Int J Cancer 2001; 94:153-156
2. Kiyosawa K, Umemura T, Ichijo T, et al. Hepatocellular carcinoma: recent trends in Japan. Gastroenterology 2004; 127:S17-S26
3. El-Serag HB, Davila JA, Petersen NJ, McGlynn KA. The continuing increase in the incidence of hepatocellular carcinoma in the United States: an update. Ann Intern Med 2003; 139:817-823
4. Taylor-Robinson SD, Foster GR, Arora S, Hargreaves S, Thomas HC. Increase in primary liver cancer in the UK, 1979-94. Lancet 1997; 350:1142-1143
5. Ikai I, Arii S, Ichida T, et al. Report of the 16th follow-up survey of primary liver cancer. Hepatol Res 2005; 32:163-172
6. Llovet JM, Real MI, Montana X, et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 2002; 359:1734-1739
7. Lo CM, Ngan H, Tso WK, et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 2002; 35:1164-1171
8. Camma C, Schepis F, Orlando A, et al. Transarterial chemoembolization for unresectable hepatocellular carcinoma: meta-analysis of randomized controlled trials. Radiology 2002; 224:47-54
9. Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology 2003; 37:429-442
10. [No authors listed]. A comparison of lipiodol chemoembolization and conservative treatment for unresectable hepatocellular carcinoma. Groupe d'Etude et de Traitement du Carcinome Hépatocellulaire. N Engl J Med 1995; 332:1256-1261
11. Pelletier G, Ducreux M, Gay F, et al. Treatment of unresectable hepatocellular carcinoma with lipiodol chemoembolization: a multicenter randomized trial. J Hepatol 1998; 29:129-134
12. Kanematsu T, Inokuchi K, Sugimachi K, et al. Selective effects of lipiodolized antitumor agents. J Surg Oncol 1984; 25:218-226
13. Ikeda K, Inoue H, Yano T, Kobayashi H, Nakajo M. Comparison of the anticancer effect of ADMOS alone and ADMOS with CDDP in the treatment of hepatocellular carcinoma by intra-arterial injection. Cancer Chemother Pharmacol 1992; 31[suppl]:S65-S68
14. Lu CD, Qi YG, Peng SY. Lipiodolization with or without gelatin sponge in hepatic arterial chemoembolization for hepatocellular carcinoma. Chin Med J (Engl) 1994; 107:209-215
15. Bhattacharya S, Novell JR, Dusheiko GM, Hilson AJ, Dick R, Hobbs KE. Epirubicin-lipiodol chemotherapy versus 131iodine-lipiodol radiotherapy in the treatment of unresectable hepatocellular carcinoma. Cancer 1995; 76:2202-2210
16. Hatanaka Y, Yamashita Y, Takahashi M, et al. Unresectable hepatocellular carcinoma: analysis of prognostic factors in transcatheter management. Radiology 1995; 195:747-752
17. Kawai S, Tani M, Okamura J, et al. Prospective and randomized trial of lipiodol-transcatheter arterial chemoembolization for treatment of hepatocellular carcinoma: a comparison of epirubicin and doxorubicin (second cooperative study). The Cooperative Study Group for Liver Cancer Treatment of Japan. Semin Oncol 1997;24[2 suppl 6]:S6-38-S6-45
18. Maeda S, Fujiyama S, Tanaka M, Ashihara H, Hirata R, Tomita K. Survival and local recurrence rates of hepatocellular carcinoma patients treated by transarterial chemolipiodolization with and without embolization. Hepatol Res 2002; 23:202-210
19. Ikeda M, Maeda S, Shibata J, et al. Transcatheter arterial chemotherapy with and without embolization in patients with hepatocellular carcinoma. Oncology 2004; 66:24-31
20. Takayasu K, Arii S, Ikai I, et al. Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patients. Gastroenterology 2006; 131:461-469
21. Takayasu K, Furukawa H, Wakao F, et al. CT diagnosis of early hepatocellular carcinoma: sensitivity, findings, and CT-pathologic correlation. AJR 1995; 164:885-890
22. Baron RL, Oliver JH 3rd, Dodd GD 3rd, Nalesnik M, Holbert BL, Carr B. Hepatocellular carcinoma: evaluation with biphasic, contrast-enhanced, helical CT. Radiology 1996; 199:505-511
23. The Liver Cancer Study Group of Japan. The general rules for the clinical and pathological study of primary liver cancer. Tokyo, Japan: Kanehara, 2003
24. Nanashima A, Sumida Y, Morino S, et al. The Japanese integrated staging score using liver damage grade for hepatocellular carcinoma in patients after hepatectomy. Eur J Surg Oncol 2004; 30: 765-770
25. Makuuchi M, Belghiti J, Belli G, et al. IHPBA concordant classification of primary liver cancer: working group report. J Hepatobiliary Pancreat Surg 2003; 10:26-30
26. Murakami T. Local therapy: radiological intervention (transcatheter arterial embolization). Tokyo: Arcmedia, 2004:182-192
27. Rosenbaum PR. Rubin DB. The central role of the propensity score in observational studies for causal effects. Biometrika 1983; 70:41-55
28. Gum PA, Thamilarasan M, Watanabe J, Blackstone EH, Lauer MS. Aspirin use and all-cause mortality among patients being evaluated for known or suspected coronary artery disease: a propensity analysis. JAMA 2001; 286:1187-1194
29. Lindenauer PK, Pekow P, Wang K, Gutierrez B, Benjamin EM. Lipid-lowering therapy and in-hospital mortality following major noncardiac surgery. JAMA 2004; 291:2092-2099
30. Takayasu K, Shima Y, Muramatsu Y, et al. Hepatocellular carcinoma: treatment with intraarterial iodized oil with and without chemotherapeutic agents. Radiology 1987; 163:345-351
31. Okayasu I, Hatakeyama S, Yoshida T, et al. Selective and persistent deposition and gradual drainage of iodized oil, lipiodol, in the hepatocellular carcinoma after injection into the feeding hepatic artery. Am J Clin Pathol 1988; 90:536-544
32. Kan Z, Sato M, Ivancev K, et al. Distribution and effect of iodized poppyseed oil in the liver after hepatic artery embolization: experimental study in several animal species. Radiology 1993; 186: 861-866
33. Okusaka T, Okada S, Ueno H, et al. Transcatheter arterial embolization with zinostatin stimalamer for hepatocellular carcinoma. Oncology 2002; 62:228-233
34. Okusaka T, Okada S, Ishii H, et al. Transarterial chemotherapy with zinostatin stimalamer for hepatocellular carcinoma. Oncology 1998; 55:276-283
35. Madden MV, Krige JE, Bailey S, et al. Randomised trial of targeted chemotherapy with lipiodol and 5-epidoxorubicin compared with symptomatic treatment for hepatoma. Gut 1993; 34: 1598-1600
36. Caturelli E, Siena DA, Fusilli S, et al. Transcatheter arterial chemoembolization for hepatocellular carcinoma in patients with cirrhosis: evaluation of damage to nontumorous liver tissue - long-term prospective study. Radiology 2000; 215:123-128
37. Varela M, Real MI, Burrel M, et al. Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics. J Hepatol 2007; 46:474-481
38. Kulik LM, Carr BI, Mulcahy MF, et al. Safety and efficacy of 90Y radiotherapy for hepatocellular carcinoma with and without portal vein thrombosis. Hepatology 2008; 47:71-81
39. Maluccio MA, Covey AM, Porat LB, et al. Transcatheter arterial embolization with only particles for the treatment of unresectable hepatocellular carcinoma. J Vasc Interv Radiol 2008; 19:862-869